GlassScriptPhysician profile
Colleen M Coleman
NPI 1215936836
$5,300.23
in general payments reported to CMS, 2019-2025
27 companies · $761 in 2025
The $761 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $216 · 2021: $488 · 2022: $567 · 2023: $1,019 · 2024: $1,199 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,619.74 | 2019-2025 | Clareon, Centurion, Hydrus Microstent |
| Sight Sciences, INC. | $551.99 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $492.46 | 2019-2024 | Idose, Radius, Photrexa Cross-Linking Kit |
| Allergan, INC. | $363.97 | 2019-2021 | |
| Rxsight INC | $305.70 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $266.92 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $180.32 | 2022-2025 | Xiidra |
| Dompe US, INC. | $154.76 | 2025 | Oxervate |
| Ethicon US, LLC | $153.14 | 2023-2024 | Stratafix, Echelon Endopath |
| New World Medical,INC. | $148.99 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140.02 | 2019 | |
| Astellas Pharma US INC | $117.43 | 2023 | Izervay |
| Novartis Pharmaceuticals Corporation | $109.16 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $101.93 | 2023 | |
| Abbvie INC. | $93.78 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $90.91 | 2019 | |
| Oyster Point Pharma, INC. | $74.16 | 2022-2023 | Tyrvaya |
| Ocular Therapeutix, INC. | $60.20 | 2020-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $47.93 | 2021 | |
| Eyepoint US, INC. | $47.00 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $45.14 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $30.63 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $28.72 | 2021 | |
| Thea Pharma INC. | $22.47 | 2023 | Iyuzeh |
| Abb Con-Cise Optical Group LLC | $21.27 | 2019 | |
| Harrow Eye, LLC | $18.00 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.